Khan Najat sold $79K of RXRX

Khan Najat (CEO and President) sold 22,408 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.52 on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khan Najat
Published Sep 10, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The CEO's sale is modest and unlikely to move the stock, but it provides transparency for investors.

02

Market read

Primary disclosure of a small insider sale; limited trading relevance.

03

What to watch

Potential tax planning or diversification motives not disclosed.

Relevance 2/10Novelty 3/10Timing: post‑market filing on 2026‑09‑10

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

CEO Khan Najat sold 22,408 shares for $78,822.38 via a 10b5‑1 plan on 2026‑09‑08.

Expected impact

Minimal short‑term impact; price likely unchanged or slightly down.

Evidence & confidence

The sale size ($79K) is small relative to the insider's remaining holdings (2.07M shares) and typical market volume, so market reaction is expected to be limited.

Market effects

No immediate sector impact; biotech sector remains unchanged.

Limited to US biotech investors.

Low global relevance.

Counterpoint

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Khan Najat

    CEO and President of Recursion Pharmaceuticals.

  • Recursion Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RXRX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.